Bloodstream Infection Testing

REPORT HIGHLIGHTS

Global Bloodstream Infection Testing Market to Reach US$1.5 Billion by 2032

The global market for Bloodstream Infection Testing estimated at US$963.8 Million in the year 2025, is expected to reach US$1.5 Billion by 2032, growing at a CAGR of 6.9% over the analysis period 2025-2032. Reagents & Consumables Offering, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Instruments Offering segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$357.4 Million While China is Forecast to Grow at 9.0% CAGR

The Bloodstream Infection Testing market in the U.S. is estimated at US$357.4 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$209.8 Million by the year 2032 trailing a CAGR of 9.0% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Bloodstream Infection Testing Market - Key Trends and Drivers Summarized

Why Is Bloodstream Infection Testing a Cornerstone in Medical Diagnostics?

Bloodstream infection (BSI) testing plays a pivotal role in medical diagnostics, as it is crucial for the early detection and treatment of sepsis, a life-threatening condition caused by an overwhelming immune response to infection. BSIs can result from a variety of pathogens, including bacteria, fungi, and viruses, and their rapid identification is essential to prevent the progression to severe sepsis or septic shock, both of which are associated with high mortality rates. Timely BSI testing allows healthcare providers to administer appropriate antimicrobial therapies, thereby reducing the risk of complications and improving patient outcomes. As a cornerstone of infection control in hospitals, BSI testing is also vital in preventing the spread of infections, particularly in critical care units where patients are most vulnerable.

How Are Technological Innovations Transforming Bloodstream Infection Testing?

The landscape of bloodstream infection testing is being transformed by rapid advancements in technology, which are enhancing the speed, accuracy, and comprehensiveness of diagnostics. Traditional blood culture methods, which can take days to deliver results, are being supplemented or replaced by advanced molecular diagnostic techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing (NGS). These technologies enable the rapid identification of pathogens, often within hours, allowing for earlier and more targeted treatment interventions. Additionally, the advent of point-of-care (POC) testing devices is bringing BSI diagnostics closer to the patient, facilitating quicker decision-making in emergency and remote healthcare settings. The integration of artificial intelligence (AI) and machine learning algorithms into diagnostic platforms is also enhancing the interpretation of complex data, leading to more accurate diagnoses and better patient management.

What Challenges and Regulatory Pressures Are Shaping the Bloodstream Infection Testing Market?

The bloodstream infection testing market is shaped by a complex interplay of challenges and regulatory pressures. One of the primary challenges is the need for highly sensitive and specific tests that can accurately identify a wide range of pathogens, including those that are difficult to culture or detect. This demand has led to significant investment in research and development, driving innovation in diagnostic technologies. At the same time, regulatory bodies such as the FDA and the European Medicines Agency impose stringent standards for the approval of new testing methods, ensuring that only the most effective and safe diagnostics are brought to market. These regulations are critical for maintaining the quality and reliability of BSI testing but also pose barriers to market entry for smaller companies and startups. Additionally, the growing concern over antibiotic resistance is influencing the development of BSI tests that can provide not only pathogen identification but also insights into antibiotic susceptibility, thereby guiding more effective treatment decisions.

What Are the Key Drivers Behind the Growth of the Bloodstream Infection Testing Market?

The growth in the bloodstream infection testing market is driven by several factors, including the rising incidence of hospital-acquired infections (HAIs) and the increasing prevalence of drug-resistant pathogens, which heighten the need for rapid and accurate diagnostics. The global burden of sepsis, particularly in aging populations and immunocompromised patients, is also fueling demand for advanced BSI testing solutions. Furthermore, the shift towards personalized medicine and the need for precise, pathogen-specific treatment regimens are driving the adoption of cutting-edge molecular diagnostics in BSI testing. Technological advancements, such as the development of automated and high-throughput testing platforms, are reducing the time to diagnosis, which is critical in managing BSIs effectively. Additionally, the expansion of healthcare infrastructure in emerging markets and the increasing awareness of sepsis among healthcare providers and the general public are contributing to market growth. As healthcare systems worldwide continue to prioritize infection control and antimicrobial stewardship, the demand for efficient and reliable bloodstream infection testing is expected to rise, driving further innovation and expansion in this critical market segment.

SCOPE OF STUDY:

The report analyzes the Bloodstream Infection Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Offering (Reagents & Consumables Offering, Instruments Offering); Sample (Blood Culture Sample, Whole Blood Sample); Technology (Conventional Testing Technology, Non-Conventional Testing Technology); End-Use (Hospitals & Diagnostic Centers End-Use, Custom Laboratory Service Providers End-Use, Academic & Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Cepheid
• Deepull Diagnostics SL
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Grifols, S.A.
• Qiagen NV
• Seegene, Inc
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.
• ZeptoMetrix LLC

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more